Compare Compass Inc. Class A Common Stock (COMP) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Compass Inc. Class A Common Stock vs Citius Pharmaceuticals Inc — how do they compare? Compass Inc. Class A Common Stock trades at $9.52 (market cap $7.05B), while Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M). The key difference: Compass Inc. Class A Common Stock is far larger — about 511.2× Citius Pharmaceuticals Inc's market cap, and Compass Inc. Class A Common Stock is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and Citius Pharmaceuticals Inc for 16 Days on average.
| COMP | CTXR | |
|---|---|---|
Market Cap | $7.05B | $13.79M |
Volume | 15,310,192 | 156,684 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $1.82 |
52-Week Low | $6.68 | $0.48 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $10.47B | $3.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Compass Inc. Class A Common Stock
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
